Synapse

← BJC Reports

Papers in BJC Reports

Page 5 · newest first

  1. Small extracellular vesicles in plasma carry luminal cytokines that remain undetectable by antibody-based assays in cancer patients and healthy donorsBJC Reports · 2024
  2. Germline sequencing in men with metastatic castration-resistant prostate cancer from the BARCODE2 study reveals a wide range of pathogenic variants in DNA repair genesBJC Reports · 2024
  3. Comparative efficacy of combined CTLA-4 and PD-1 blockade vs. PD-1 monotherapy in metastatic melanoma: a real-world studyBJC Reports · 2024
  4. Incidental finding of leukaemia in circulating tumour DNA— the importance of a molecular tumour boardBJC Reports · 2024
  5. Protein prognostic biomarkers in stage II colorectal cancer: implications for post-operative managementBJC Reports · 2024
  6. Spatial functional mapping of hypoxia inducible factor heterodimerisation and immune checkpoint regulators in clear cell renal cell carcinomaBJC Reports · 2024
  7. PTEN pathogenic variants are associated with poor prognosis in patients with advanced soft tissue sarcomaBJC Reports · 2024
  8. Results and lessons learnt from the WISTERIA phase I trial combining AZD1775 with cisplatin pre- or post-operatively in head and neck cancerBJC Reports · 2024
  9. Impact of underlying liver disease on unresectable hepatocellular carcinoma treated with immune checkpoint inhibitorsBJC Reports · 2024
  10. Expression of transglutaminase-2 (TGM2) in the prognosis of female invasive breast cancerBJC Reports · 2024
  11. Artificial intelligence-powered discovery of small molecules inhibiting CTLA-4 in cancerBJC Reports · 2024
  12. A Phase 2 study of nivolumab in combination with modified FOLFIRINOX for metastatic pancreatic cancerBJC Reports · 2024
  13. Patterns of referrals to regional clinical genetics services for women potentially at above-population level risk of breast cancerBJC Reports · 2024
  14. Metformin may improve the outcome of patients with colorectal cancer and type 2 diabetes mellitus partly through effects on neutrophil extracellular trapsBJC Reports · 2023
  15. Identification of cancer driver mutations in liquid-based cytology samples for the screening of endometrial diseasesBJC Reports · 2023
  16. Direct administration of human leucocyte antigen (dHLA) molecules into tumour sites: proposal for a new immunotherapy for cancerBJC Reports · 2023
  17. Developing a risk prediction tool for lung cancer in Kent and Medway, England: cohort study using linked dataBJC Reports · 2023
  18. An apparent quandary: adoption of polygenics and gene panels for personalised breast cancer risk stratificationBJC Reports · 2023
  19. Best analgesia control in pancreatic adenocarcinoma study: justification and feasibility of a randomised trial of early EUS-CPN versus standard care—a prospective observational study (The BAC-PAC study)BJC Reports · 2023
  20. Prevalence of the human papillomavirus (HPV) types among cervical dysplasia women attending a gynaecological clinic in SwedenBJC Reports · 2023
  21. Gut microbiome and nutrition-related predictors of response to immunotherapy in cancer: making sense of the puzzleBJC Reports · 2023
  22. C-reactive protein kinetics as a predictive marker for long-term outcome of immune checkpoint inhibitors in oesophagogastric cancerBJC Reports · 2023
  23. The role of virtual consultations in cancer genetics: challenges and opportunities introduced by the COVID-19 pandemicBJC Reports · 2023
  24. Radiomics and outcome prediction to antiangiogenic treatment in advanced gastroenteropancreatic neuroendocrine tumours: findings from the phase II TALENT trialBJC Reports · 2023
  25. Lung cancer in never smokers (LCINS): development of a UK national research strategyBJC Reports · 2023
  26. The amino-acid stress sensing eIF2α kinase GCN2 is a survival biomarker for malignant mesotheliomaBJC Reports · 2023
  27. Relationship between 233 colorectal cancer risk loci and survival in 1926 patients with advanced diseaseBJC Reports · 2023
  28. UK recommendations for the management of transgender and gender-diverse patients with inherited cancer risksBJC Reports · 2023